In an elderly patient taking 150 mg of trazodone nightly for insomnia without adequate effect, is it appropriate to increase the dose?

Do Not Increase the Trazodone Dose

I recommend against increasing the trazodone dose in this elderly patient and instead switching to an FDA-approved medication for insomnia. The most recent and highest-quality guideline evidence explicitly advises against using trazodone for chronic insomnia treatment 1.

Why Trazodone Should Not Be Increased

The 2020 VA/DoD Clinical Practice Guidelines—the most recent and authoritative source—specifically recommend against using trazodone for chronic insomnia disorder 1. This recommendation is based on systematic reviews showing:

• No significant improvement in sleep efficiency, sleep onset latency, total sleep time, or wake after sleep onset compared to placebo (dose range 50-150 mg) 1
• Only modest improvement in subjective sleep quality, but this does not translate to objective sleep measures
• The adverse effect profile outweighs the limited benefits, particularly in elderly patients 1

Critical Safety Concerns in the Elderly

Trazodone poses specific risks for your elderly patient:

• Falls and dizziness are common adverse effects 2, 3
• Recent evidence shows trazodone is associated with 3.1 times higher mortality risk compared to alternatives in older adults 2
• 8.1 times higher risk of dementia compared to trazodone alternatives 2
• 2.8 times higher risk of falls 2
• Orthostatic hypotension and syncope are well-documented 4
• Sedation and next-morning impairment affecting daily function 3

Lack of FDA Approval and Evidence

Trazodone is not FDA-approved for insomnia 5. The FDA label indicates its approved use is for depression at doses of 150-600 mg daily 4. When used off-label for insomnia, the evidence base is extremely weak:

• Studies are small, short-duration (mean 1.7 weeks), and primarily in depressed populations 1
• The 2008 AASM guidelines note that "efficacy for this indication is not well established" 5
• The 2017 AASM guideline explicitly suggests clinicians NOT use trazodone for sleep onset or maintenance insomnia 6

What to Do Instead

First-Line Approach: Switch to Evidence-Based Medication

Consider switching to a nonbenzodiazepine benzodiazepine receptor agonist (BZRA) at the lowest effective dose 1:

For sleep onset insomnia:

• Zolpidem 5 mg at bedtime (elderly dose) 5
• Zaleplon 5 mg at bedtime (elderly dose) 5

For sleep maintenance insomnia:

• Eszopiclone 1 mg at bedtime (elderly dose, max 2 mg) 5
• Low-dose doxepin 3 mg at bedtime (specifically studied in older adults with good efficacy) 1

These agents have demonstrated efficacy in improving sleep efficiency, sleep onset latency, sleep quality, total sleep time, and wake after sleep onset compared to placebo 1.

Important Counseling Points

When prescribing any hypnotic to elderly patients:

• Start at the lowest available dose 5, 7, 5
• Counsel about FDA warnings regarding complex sleep behaviors (sleepwalking, sleep driving) 5, 1
• Use for the shortest possible duration 1
• Avoid combining with alcohol or other CNS depressants 5
• Allow adequate sleep time (7-8 hours) before activities requiring alertness 5
• Monitor for next-morning impairment, especially with driving 8

Alternative Consideration

If the patient has comorbid depression requiring treatment, consider:

• Low-dose doxepin 3-6 mg specifically for sleep maintenance (has better evidence than trazodone in elderly) 1
• If full antidepressant therapy is needed, treat the depression adequately with an appropriate antidepressant at therapeutic doses, then add a separate FDA-approved hypnotic if insomnia persists 5

Common Pitfall to Avoid

Do not simply increase trazodone to 200-300 mg thinking higher doses will work better. While the FDA label mentions doses up to 400 mg for outpatients with depression 4, this:

• Increases adverse effects without proven benefit for insomnia 1, 9
• Exposes elderly patients to unacceptable risks (falls, cognitive impairment, orthostatic hypotension) 4, 2
• Still lacks efficacy data for insomnia even at higher doses 1, 9

The evidence is clear: trazodone's risks outweigh its minimal benefits for insomnia in elderly patients, and dose escalation will not solve the problem 1, 2.